{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cyclo Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"CYTHW"},"Address":{"label":"Address","value":"6714 NW 16TH STREET,SUITE B, GAINESVILLE, Florida, 32653, United States"},"Phone":{"label":"Phone","value":"+1 386 418-8060"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its lead drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex."},"CompanyUrl":{"label":"Company Url","value":"https://www.cyclotherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jeffrey L. Tate","title":"Director, Chief Operating & Quality Officer"},{"name":"Karen Mullen","title":"Chief Medical Officer"},{"name":"Nathan Scott Fine","title":"Chief Executive Officer & Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}